Table 1.
Study No. | Disease (Leishmania species) | Endemic region | L-AmB regimen | Total dose | No. of patients | % Cure (month assessed) | Ref. |
---|---|---|---|---|---|---|---|
1 | VL (L. donovani) | Indian subcontinent | AmB (deoxycholate) 1 mg/kg qod × 15 injs | 15 mg/kg | 108 | 96.3 (6 months) | 1 |
2 | VL (L. donovani) | Indian subcontinent | 10 mg/kg × 1 inj | 10 mg/kg | 304 | 95.7 (6 months) | 1 |
3 | VL (L. donovani) | Indian subcontinent | 10 mg/kg × 1 inj | 10 mg/kg | 1,143 | 94 (12 months) | 2 |
4 | VL (L. donovani) | East Africa | 10 mg/kg × 1 inj | 10 mg/kg | 40 | 58 (6 months) | 4 |
3 mg/kg × 7 injs over 21 days | 21 mg/kg | 54 | 85 (6 months) | 4 | |||
5 | VL (L. infantum) | Europe | 1–1.4 mg/kg/day × 21 days | 21–29 mg/kg | 10 | 100 (12 months) | 5 |
3 mg/kg/day × 10 days | 30 mg/kg | 10 | 100 (12 months) | 5 | |||
6 | VL (L. chagasi) | Brazil | 3 mg/kg/day × 7 days | 21 mg/kg | 109 | 87 (6 months) | 7 |
7 | VL (L. chagasi) | Brazil | 2 mg/kg/day × 7 injs over 10 days | 14 mg/kg | 13 | 62 (6 months) | 8 |
8 | CL (L. tropica) | Old World | 3 mg/kg on days 1–5 and 10 | 18 mg/kg | 13 | 84 (11 months) | 12 |
9 | CL (L. braziliensis) | New World | 3 mg/kg on days 1–5 and 10 | 18 mg/kg | 34 | 97 (2 years) | 13 |
10 | ML | New World | Not available | 30–35 mg/kg | 16 | 88 (1 year) | 15 |
11 | PKDL | Indian subcontinent | (2 courses of) 5 mg/kg qod × 4 injs | 40 mg/kg | 4 | 100 | 17 |
12 | PKDL | Indian subcontinent | 3 mg/kg × 5 injs over 15 days | 15 mg/kg | 273 | 78 (12 months) | 18 |
CL = cutaneous leishmaniasis; injs = injections; ML = mucosal leishmaniasis; qod = every other day; PKDL = post–kala-azar dermal leishmaniasis; VL = visceral leishmaniasis.